GoodRx Announces $250 Million Share Repurchase Program

Go back to GoodRx Announces $250 Million Share Repurchase Program

GoodRx Holdings Inc. (GDRX) PT Lowered to $20 at JPMorgan

March 1, 2022 4:58 AM EST

JPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.

The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More

GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook

February 28, 2022 5:31 PM EST

GoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the companys disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.

Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year... More

GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street

February 28, 2022 4:13 PM EST

GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q4 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $217.53 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q1 2022 revenue of ~$200 million, versus the... More